# Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

> **NCT00329446** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 800 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Quetiapine Fumarate
- **DRUG:** Escitalopram oxylate

## Key facts

- **NCT ID:** NCT00329446
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329446, "Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00329446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*